← 產業報告目錄

Central Lab Services/Clinical Trial Lab Services Market by Phase (Phase I, II, III), Service Type (Safety Testing, Immunology), Therapeutic Area (Oncology), Modality (Small Molecules, Vaccine), End user (Pharma & CROs) & Region - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-03-18頁數 311報告編號 PH9332

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global Central lab services/clinical trial lab services market is projected to reach USD 8.18 billion by 2030 from USD 5.97 billion in 2025, at a CAGR of 6.5% during the forecast period. This is due to increasing adoption of drug discovery, as the adoption increases the demand for these services rises. Additionally, increasing government support to provide grants for healthcare is increasing, thus rising the number of clinical trials, consequently increasing the demand for the central lab clinical service trial. However, the high cost associated with the clinical trial methods are the major restraint to the market. Additionally, the shortage of trained healthcare professionals & limited knowledge about the services is major challenge for the market growth. But is creating a conducive environment for market expansion over the forecast period of 2025-2030. “The pharmaceutical & biopharmaceutical companies segment of central lab services/clinical trial lab services market by end user to hold largest position forecast period.” Based on the end user, the central lab services/clinical trial lab services market is divided into pharmaceutical & biopharmaceutical companies, CROS, medical device companies, and other end users. Among these, in 2024 pharmaceutical & biopharmaceutical companie segment account for the largest market share of 61.8% in central lab services/clinical trial lab services market. This is due to the rising prevalence of rare disease. Majority of the pharmaceutical companies are conducting the clinical trials for the cure of such diseases via advanced technologies. Thus, majority of the companies prefer these services. Thus, as the prevalence of these diseases is increasing the need for long term treatment is rising, consequently increasing the demand for central lab services/clinical trial lab services market. “The oncology segment accounts for the largest market share in central lab services/clinical trial lab services market.” Based on theraprutic area, the central lab services/clinical trial lab services market is segmented into oncology, infectious diseases, neurology, cardiology, and other therapeutic areas. The oncology segment holds for the largest market share in central lab services/clinical trial lab services market due to increasing number of cancer patients. Oncology clinical trials often require modern diagnostic testing, including biomarker testing, genomic testing, and tumor profiling, to assess the effectiveness and safety of new cancer therapies in clinical trials. Central labs are important in providing these services, ensuring that testing is viable, consistent, and compliant with regulatory standards across multiple sites. With the rising focus on precision medicine, the need for specialized and high-quality lab testing in oncology is significant, making the oncology segment the largest and most critical in the central lab services market. “Asia Pacific is the fastest growing region of the central lab services/clinical trial lab services market by region.” The global central lab services/clinical trial lab services market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing regional market for entral lab services/clinical trial lab services and is estimated to grow at the highest CAGR during the forecast period. This is due to increasing prevalence of rare diseases and rising population across the region. Asia Pacific region includes Japan, China, India, and Rest of Asia Pacific. Among these, China accounts for the largest market share in central lab services/clinical trial lab services market in 2024. This is due to its rapid expansion of pharmaceutical and biotechnology industries, added with the with a large patient population and increasing demand for innovative treatments. The country's growing healthcare infrastructure, investment in clinical research, and supportive regulatory environment have made it an attractive hub for global clinical trials. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16% • By Designation: C-level–25%, Director-level–30% and Others–45% • By Region: North America–40%, Europe–25%, Asia Pacific–20%, Latin America- 10%, and Middle east and Africa – 5% Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion. Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs. Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers. The major players operating in the central lab services/clinical trial lab services market are Thermo Fisher Scientific Inc. (US), IQVIA (US), ICON plc (Ireland), Labcorp (US), Quest Diagnostics (US), Charles River Laboratories (US), Medpace (US), Frontage lab (US), SGS Société Générale de Surveillance SA (Switzerland), Eurofins Scientific (Luxembourg), and REPROCELL Inc. (Japan). Research Coverage This report studies the central lab services/clinical trial lab services market based on product, type, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions). Reasons to Buy the Report The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence. This report provides insights on the following pointers: • Analysis of Key divers (Increasing number of clinical trials, increasing investments in research & development, growing prevalence of rare diseases), restraints (High cost associated with clinicaltrials, Shortage of skilled professionals), opportunity (Emerging markets worldwide, decentralized and virtual clinical trials), Challenge (regulatory complexities, limited patient diversity and cybersecurity or intellectual property concerns) • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the central lab services/clinical trial lab services market • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the central lab services/clinical trial lab services market • Market Development: Comprehensive information on lucrative emerging regions • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pain management devices market • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
目錄 Table of Contents
1 INTRODUCTION 31 1.1 STUDY OBJECTIVES 31 1.2 MARKET DEFINITION 31 1.3 STUDY SCOPE 32 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 32 1.3.2 INCLUSIONS AND EXCLUSIONS 33 1.3.3 YEARS CONSIDERED 34 1.4 CURRENCY CONSIDERED 34 1.5 STAKEHOLDERS 34 2 RESEARCH METHODOLOGY 35 2.1 RESEARCH DATA 35 2.1.1 SECONDARY DATA 35 2.1.1.1 Key data from secondary sources 36 2.1.2 PRIMARY DATA 37 2.1.2.1 Primary sources 37 2.1.2.2 Key industry insights 38 2.1.2.3 Key data from primary sources 38 2.1.2.4 Breakdown of primary interviews 40 2.2 MARKET SIZE ESTIMATION 40 2.2.1 BOTTOM-UP APPROACH 40 2.2.1.1 Approach 1: Company revenue estimation approach 41 2.2.1.2 Approach 2: Presentations of companies and primary interviews 41 2.2.1.3 Approach 3: Primary interviews 41 2.2.1.4 Growth forecast 41 2.2.1.5 CAGR projections 42 2.2.2 TOP-DOWN APPROACH 42 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 43 2.4 RESEARCH ASSUMPTIONS 45 2.4.1 STUDY-RELATED ASSUMPTIONS 45 2.4.2 PARAMETRIC ASSUMPTIONS 45 2.5 RESEARCH LIMITATIONS 46 2.6 RISK ASSESSMENT 46 3 EXECUTIVE SUMMARY 47   4 PREMIUM INSIGHTS 52 4.1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET OVERVIEW 52 4.2 ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER AND COUNTRY 53 4.3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY 54 4.4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, REGIONAL MIX, 2025 VS. 2030 55 5 MARKET OVERVIEW 56 5.1 INTRODUCTION 56 5.2 MARKET DYNAMICS 56 5.2.1 DRIVERS 57 5.2.1.1 Increasing number of clinical trials 57 5.2.1.2 Rising investments in research & development 57 5.2.1.3 Growing prevalence of rare diseases 58 5.2.1.4 Favorable government initiatives 59 5.2.2 RESTRAINTS 59 5.2.2.1 High costs associated with clinical trials 59 5.2.2.2 Shortage of skilled professionals 60 5.2.3 OPPORTUNITIES 61 5.2.3.1 Emerging markets worldwide 61 5.2.3.2 Decentralized and virtual clinical trials 61 5.2.4 CHALLENGES 62 5.2.4.1 Regulatory complexities 62 5.2.4.2 Limited patient diversity 63 5.2.4.3 Cybersecurity and intellectual property concerns 63 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 64 5.4 VALUE CHAIN ANALYSIS 65 5.4.1 RESOURCE ACQUISITION AND PREPARATION 65 5.4.2 CLINICAL TRIAL EXECUTION 65 5.4.3 DATA REPORTING AND RESULT SUBMISSION 65 5.4.4 PROMOTION AND REGULATORY FILING 65 5.5 ECOSYSTEM ANALYSIS 66 5.6 INVESTMENT AND FUNDING SCENARIO 68 5.7 TECHNOLOGY ANALYSIS 68 5.7.1 KEY TECHNOLOGIES 68 5.7.1.1 Enzyme-linked immunosorbent assay 68 5.7.2 ADJACENT TECHNOLOGIES 69 5.7.2.1 Next-generation sequencing 69 5.8 KEY CONFERENCES AND EVENTS, 2025–2026 70 5.9 CASE STUDY ANALYSIS 71 5.9.1 PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY AND SAFETY OF TWO COMBINATION THERAPIES (CERBA RESEARCH) 71 5.10 REGULATORY LANDSCAPE 72 5.10.1 REGULATORY FRAMEWORK 72 5.10.1.1 North America 72 5.10.1.2 Europe 73 5.10.1.3 Asia Pacific 73 5.10.1.4 Rest of the World 74 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 5.11 PORTER’S FIVE FORCES ANALYSIS 81 5.11.1 THREAT OF NEW ENTRANTS 82 5.11.2 THREAT OF SUBSTITUTES 82 5.11.3 BARGAINING POWER OF SUPPLIERS 82 5.11.4 BARGAINING POWER OF BUYERS 82 5.11.5 INTENSITY OF COMPETITIVE RIVALRY 83 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 83 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 83 5.12.2 BUYING CRITERIA 84 5.13 IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET 85 5.13.1 INTRODUCTION 85 5.13.2 MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES 85 5.13.3 AI USE CASES 86 5.13.4 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM 87 6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE 88 6.1 INTRODUCTION 89 6.2 PHASE I 89 6.2.1 NEED TO ASSESS SAFETY, DOSAGE, AND POTENTIAL SIDE EFFECTS OF DRUGS TO AID GROWTH 89 6.3 PHASE II 91 6.3.1 NEED TO EVALUATE DESIRED EFFECT AND ADDITIONAL SAFETY DATA OF DRUGS TO DRIVE MARKET 91 6.4 PHASE III 94 6.4.1 RISING INCLINATION TOWARD CONFIRMING SAFETY AND EFFICACY OF DRUGS TO BOOST MARKET 94 6.5 PHASE IV 96 6.5.1 ONGOING SAFETY SURVEILLANCE ON DRUG TRIALS TO AUGMENT GROWTH 96   7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE 100 7.1 INTRODUCTION 101 7.2 SAFETY TESTING 101 7.2.1 NEED TO ENSURE COMPLIANCE WITH SAFETY STANDARDS TO PROMOTE GROWTH 101 7.3 IMMUNOLOGY 103 7.3.1 INCREASING FOCUS ON IMMUNOTHERAPIES TO STIMULATE GROWTH 103 7.4 GENETIC TESTING 105 7.4.1 GROWING ADVANCEMENTS IN NEXT-GENERATION SEQUENCING TO DRIVE MARKET 105 7.5 COAGULATION TESTING 107 7.5.1 ESSENTIAL ROLE IN MONITORING COAGULATION DISORDERS AND EVALUATING ANTICOAGULANT THERAPIES TO EXPEDITE GROWTH 107 7.6 PATHOLOGY TESTING 109 7.6.1 ABILITY TO PROVIDE INSIGHTS INTO DISEASE MECHANISMS, TREATMENT EFFECTS, AND DIAGNOSTICS TO AID GROWTH 109 7.7 BIOMARKERS 112 7.7.1 NEED TO EXAMINE TEST EFFECTS ON PATIENTS TO AUGMENT GROWTH 112 7.8 COMPANION DIAGNOSTICS 113 7.8.1 GROWING INCLINATION TOWARD PERSONALIZED TREATMENTS TO DRIVE MARKET 113 7.9 OTHER TESTS 116 8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA 118 8.1 INTRODUCTION 119 8.2 ONCOLOGY 119 8.2.1 INCREASING CANCER RESEARCH STUDIES TO ACCELERATE GROWTH 119 8.3 INFECTIOUS DISEASES 121 8.3.1 INCREASING CASES OF INFECTIOUS DISEASES TO ENCOURAGE GROWTH 121 8.4 NEUROLOGY 124 8.4.1 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO FACILITATE GROWTH 124 8.5 CARDIOLOGY 126 8.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET 126 8.6 OTHER THERAPEUTIC AREAS 128   9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY 131 9.1 INTRODUCTION 132 9.2 SMALL MOLECULES 132 9.2.1 EMERGENCE OF THERAPEUTIC MODALITIES TO AMPLIFY GROWTH 132 9.3 BIOLOGICS 134 9.3.1 MONOCLONAL ANTIBODIES 136 9.3.1.1 Growing advancements in antibody engineering to drive market 136 9.3.2 VACCINES 138 9.3.2.1 Increasing investments in vaccine development to favor growth 138 9.3.3 OTHER THERAPEUTIC PRODUCTS 140 9.4 CELL & GENE THERAPY 142 9.4.1 OUTSOURCING TREND TO FAVOR GROWTH 142 9.5 MEDICAL DEVICES & IVD DEVICES 144 9.5.1 RISING FOCUS ON REAL-TIME PATIENT HEALTH TRACKING TO BOOST MARKET 144 10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER 147 10.1 INTRODUCTION 148 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 148 10.2.1 EMERGING BIOPHARMA COMPANIES TO EXPEDITE GROWTH 148 10.3 CLINICAL RESEARCH ORGANIZATIONS 151 10.3.1 CRITICAL ROLE IN SITE SELECTION, RECRUITMENT SUPPORT, CLINICAL MONITORING, AND DATA COLLECTION TO DRIVE MARKET 151 10.4 MEDICAL DEVICE COMPANIES 153 10.4.1 RISING FOCUS ON QUALITY AND SAFETY STANDARDS TO STIMULATE GROWTH 153 10.5 OTHER END USERS 155 11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY REGION 157 11.1 INTRODUCTION 158 11.2 NORTH AMERICA 158 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 159 11.2.2 US 164 11.2.2.1 Increasing clinical trials to support growth 164 11.2.3 CANADA 168 11.2.3.1 Rising incidence of chronic diseases to advance growth 168 11.3 EUROPE 172 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 173 11.3.2 GERMANY 177 11.3.2.1 Increasing healthcare expenditure to intensify growth 177 11.3.3 FRANCE 181 11.3.3.1 Growing investments in life sciences sector to boost market 181 11.3.4 UK 184 11.3.4.1 High number of oncology clinical trials to facilitate growth 184 11.3.5 ITALY 188 11.3.5.1 Rising focus on streamlining clinical trial process to expedite growth 188 11.3.6 SPAIN 192 11.3.6.1 Emerging biotech companies to bolster growth 192 11.3.7 REST OF EUROPE 195 11.4 ASIA PACIFIC 199 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 199 11.4.2 JAPAN 204 11.4.2.1 Growing demand for drug development to propel market 204 11.4.3 CHINA 208 11.4.3.1 Booming pharmaceutical industry to drive market 208 11.4.4 INDIA 212 11.4.4.1 Increasing regulatory reforms to foster growth 212 11.4.5 REST OF ASIA PACIFIC 216 11.5 LATIN AMERICA 219 11.5.1 ROBUST MANUFACTURING INFRASTRUCTURE TO SUSTAIN GROWTH 219 11.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 221 11.6 MIDDLE EAST & AFRICA 224 11.6.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO FUEL MARKET 224 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 225 12 COMPETITIVE LANDSCAPE 229 12.1 OVERVIEW 229 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 229 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET 229 12.3 REVENUE ANALYSIS, 2020−2024 231 12.4 MARKET SHARE ANALYSIS, 2024 233 12.5 COMPANY VALUATION AND FINANCIAL METRICS 235 12.6 BRAND/PRODUCT COMPARISON 236 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 237 12.7.1 STARS 237 12.7.2 EMERGING LEADERS 237 12.7.3 PERVASIVE PLAYERS 237 12.7.4 PARTICIPANTS 237 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 239 12.7.5.1 Company footprint 239 12.7.5.2 Region footprint 240 12.7.5.3 Product type footprint 241 12.7.5.4 Therapeutic area footprint 242 12.7.5.5 Phase footprint 243 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 244 12.8.1 PROGRESSIVE COMPANIES 244 12.8.2 RESPONSIVE COMPANIES 244 12.8.3 DYNAMIC COMPANIES 244 12.8.4 STARTING BLOCKS 244 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 246 12.8.5.1 Detailed list of key startups/SMEs 246 12.8.5.2 Competitive benchmarking of key startups/SMEs 247 12.9 COMPETITIVE SCENARIO 248 12.9.1 PRODUCT LAUNCHES 248 12.9.2 DEALS 249 12.9.3 EXPANSIONS 250 12.9.4 OTHER DEVELOPMENTS 250 13 COMPANY PROFILES 251 13.1 KEY PLAYERS 251 13.1.1 THERMO FISHER SCIENTIFIC INC. 251 13.1.1.1 Business overview 251 13.1.1.2 Products/Services offered 252 13.1.1.3 Recent developments 253 13.1.1.3.1 Product launches 253 13.1.1.3.2 Deals 253 13.1.1.3.3 Expansions 254 13.1.1.4 MnM view 254 13.1.1.4.1 Key strengths 254 13.1.1.4.2 Strategic choices 254 13.1.1.4.3 Weaknesses and competitive threats 254 13.1.2 IQVIA 255 13.1.2.1 Business overview 255 13.1.2.2 Products/Services offered 256 13.1.2.3 Recent developments 257 13.1.2.3.1 Product launches 257 13.1.2.3.2 Deals 258 13.1.2.4 MnM view 258 13.1.2.4.1 Right to win 258 13.1.2.4.2 Strategic choices 258 13.1.2.4.3 Weaknesses and competitive threats 258   13.1.3 ICON PLC 259 13.1.3.1 Business overview 259 13.1.3.2 Products/Services offered 260 13.1.3.3 Recent developments 260 13.1.3.3.1 Product launches 260 13.1.3.3.2 Deals 261 13.1.3.4 MnM view 261 13.1.3.4.1 Right to win 261 13.1.3.4.2 Strategic choices 261 13.1.3.4.3 Weaknesses and competitive threats 261 13.1.4 CHARLES RIVER LABORATORIES 262 13.1.4.1 Business overview 262 13.1.4.2 Products/Services offered 263 13.1.4.3 Recent developments 264 13.1.4.3.1 Deals 264 13.1.4.3.2 Expansions 265 13.1.4.4 MnM view 265 13.1.4.4.1 Right to win 265 13.1.4.4.2 Strategic choices 265 13.1.4.4.3 Weaknesses and competitive threats 265 13.1.5 LABCORP 266 13.1.5.1 Business overview 266 13.1.5.2 Products/Services offered 267 13.1.5.3 Recent developments 268 13.1.5.3.1 Product launches 268 13.1.5.3.2 Deals 268 13.1.5.3.3 Expansions 269 13.1.5.3.4 Other developments 269 13.1.5.4 MnM view 270 13.1.5.4.1 Key strengths 270 13.1.5.4.2 Strategic choices 270 13.1.5.4.3 Weaknesses and competitive threats 270 13.1.6 QUEST DIAGNOSTICS 271 13.1.6.1 Business overview 271 13.1.6.2 Products/Services offered 272 13.1.6.3 Recent developments 272 13.1.6.3.1 Deals 272 13.1.7 MEDPACE 274 13.1.7.1 Business overview 274 13.1.7.2 Products/Services offered 275 13.1.7.3 Recent developments 275 13.1.7.3.1 Expansions 275 13.1.8 FRONTAGE LABS 276 13.1.8.1 Business overview 276 13.1.8.2 Products/Services offered 277 13.1.9 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA 279 13.1.9.1 Business overview 279 13.1.9.2 Products/Services offered 280 13.1.9.3 Recent developments 281 13.1.9.3.1 Deals 281 13.1.10 EUROFINS SCIENTIFIC 282 13.1.10.1 Business overview 282 13.1.10.2 Products/Services offered 283 13.1.10.3 Recent developments 284 13.1.10.3.1 Deals 284 13.1.11 REPROCELL INC. 285 13.1.11.1 Business overview 285 13.1.11.2 Products/Services offered 285 13.1.11.3 Recent developments 286 13.1.11.3.1 Deals 286 13.1.12 ACM GLOBAL LABORATORIES 287 13.1.12.1 Business overview 287 13.1.12.2 Products/Services offered 287 13.1.12.3 Recent developments 288 13.1.12.3.1 Deals 288 13.2 OTHER PLAYERS 289 13.2.1 WORLDWIDE CLINICAL TRIALS 289 13.2.2 VERSITI 290 13.2.3 CTI CLINICAL TRIAL & CONSULTING 291 13.2.4 CLARITY LABORATORIES, INC 292 13.2.5 NOVOTECH 293 13.2.6 ARUP LABORATORIES 294 13.2.7 PRECISION MEDICINE GROUP 295 13.2.8 BIOAGILYTIX LABS 296 13.2.9 CERBA HEALTHCARE 297 13.2.10 ALMAC GROUP 298 13.2.11 MLM MEDICAL LABS 299 13.2.12 SALVUS BIORESEARCH SOLUTIONS LLP 300 13.2.13 UNILABS 301   14 APPENDIX 302 14.1 DISCUSSION GUIDE 302 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 307 14.3 CUSTOMIZATION OPTIONS 309 14.4 RELATED REPORTS 309 14.5 AUTHOR DETAILS 310
圖表清單 List of Tables & Figures
TABLE 1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: INCLUSIONS AND EXCLUSIONS 33 TABLE 2 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: RISK ASSESSMENT 46 TABLE 3 TRADITIONAL VS. VIRTUAL CLINICAL TRIALS 62 TABLE 4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 67 TABLE 5 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: KEY CONFERENCES AND EVENTS, 2025−2026 70 TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76 TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77 TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77 TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 11 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES 78 TABLE 12 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 81 TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 84 TABLE 14 KEY BUYING CRITERIA, BY END USER 84 TABLE 15 KEY COMPANIES IMPLEMENTING AI 86 TABLE 16 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 89 TABLE 18 COMPANIES PROVIDING PHASE I SERVICES 90 TABLE 19 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I, BY REGION, 2022–2030 (USD MILLION) 90 TABLE 20 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 90 TABLE 22 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 91 TABLE 23 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 91 TABLE 24 COMPANIES PROVIDING PHASE II SERVICES 92 TABLE 25 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY REGION, 2022–2030 (USD MILLION) 92 TABLE 26 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 93 TABLE 27 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 93 TABLE 28 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 94 TABLE 29 COMPANIES PROVIDING PHASE III SERVICES 95 TABLE 30 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY REGION, 2022–2030 (USD MILLION) 95 TABLE 31 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 95 TABLE 32 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 96 TABLE 33 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 96 TABLE 34 COMPANIES PROVIDING PHASE IV SERVICES 97 TABLE 35 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY REGION, 2022–2030 (USD MILLION) 98 TABLE 36 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 98 TABLE 37 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 99 TABLE 38 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 99 TABLE 39 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 101 TABLE 40 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY REGION, 2022–2030 (USD MILLION) 102 TABLE 41 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 102 TABLE 42 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 103 TABLE 43 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 103 TABLE 44 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY REGION, 2022–2030 (USD MILLION) 104 TABLE 45 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 104 TABLE 46 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 105 TABLE 47 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 105 TABLE 48 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY REGION, 2022–2030 (USD MILLION) 106 TABLE 49 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 106 TABLE 50 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 107 TABLE 51 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 107 TABLE 52 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY REGION, 2022–2030 (USD MILLION) 108 TABLE 53 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 108 TABLE 54 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 109 TABLE 55 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 109 TABLE 56 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY REGION, 2022–2030 (USD MILLION) 110 TABLE 57 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 110 TABLE 58 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 111 TABLE 59 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 111 TABLE 60 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY REGION, 2022–2030 (USD MILLION) 112 TABLE 61 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022–2030 (USD MILLION) 112 TABLE 62 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022–2030 (USD MILLION) 113 TABLE 63 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022–2030 (USD MILLION) 113 TABLE 64 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY REGION, 2022–2030 (USD MILLION) 114 TABLE 65 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 115 TABLE 66 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 115 TABLE 67 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 115 TABLE 68 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY REGION, 2022–2030 (USD MILLION) 116 TABLE 69 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 117 TABLE 70 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 117 TABLE 71 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 117 TABLE 72 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 119 TABLE 73 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY REGION, 2022–2030 (USD MILLION) 120 TABLE 74 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 120 TABLE 75 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 121 TABLE 76 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 121 TABLE 77 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2030 (USD MILLION) 122 TABLE 78 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 123 TABLE 79 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 123 TABLE 80 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 123 TABLE 81 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY REGION, 2022–2030 (USD MILLION) 124 TABLE 82 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 125 TABLE 83 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 125 TABLE 84 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 125 TABLE 85 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY REGION, 2022–2030 (USD MILLION) 126 TABLE 86 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 127 TABLE 87 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 127 TABLE 88 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 127 TABLE 89 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2030 (USD MILLION) 129 TABLE 90 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 129 TABLE 91 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 130 TABLE 92 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 130 TABLE 93 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 132 TABLE 94 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2022–2030 (USD MILLION) 133 TABLE 95 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022–2030 (USD MILLION) 133 TABLE 96 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022–2030 (USD MILLION) 134 TABLE 97 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022–2030 (USD MILLION) 134 TABLE 98 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 135 TABLE 99 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY REGION, 2022–2030 (USD MILLION) 135 TABLE 100 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2030 (USD MILLION) 135 TABLE 101 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2030 (USD MILLION) 136 TABLE 102 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2030 (USD MILLION) 136 TABLE 103 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022–2030 (USD MILLION) 137 TABLE 104 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2030 (USD MILLION) 137 TABLE 105 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2030 (USD MILLION) 138 TABLE 106 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2030 (USD MILLION) 138 TABLE 107 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY REGION, 2022–2030 (USD MILLION) 139 TABLE 108 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022–2030 (USD MILLION) 139 TABLE 109 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022–2030 (USD MILLION) 140 TABLE 110 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022–2030 (USD MILLION) 140 TABLE 111 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY REGION, 2022–2030 (USD MILLION) 141 TABLE 112 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 141 TABLE 113 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 142 TABLE 114 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 142 TABLE 115 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2022–2030 (USD MILLION) 143 TABLE 116 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2030 (USD MILLION) 143 TABLE 117 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2030 (USD MILLION) 144 TABLE 118 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2030 (USD MILLION) 144 TABLE 119 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY REGION, 2022–2030 (USD MILLION) 145 TABLE 120 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022–2030 (USD MILLION) 145 TABLE 121 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022–2030 (USD MILLION) 146 TABLE 122 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022–2030 (USD MILLION) 146 TABLE 123 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 148 TABLE 124 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2030 (USD MILLION) 149 TABLE 125 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 149 TABLE 126 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 150 TABLE 127 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 150 TABLE 128 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY REGION, 2022–2030 (USD MILLION) 151 TABLE 129 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022–2030 (USD MILLION) 152 TABLE 130 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022–2030 (USD MILLION) 152 TABLE 131 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022–2030 (USD MILLION) 152 TABLE 132 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022–2030 (USD MILLION) 153 TABLE 133 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 154 TABLE 134 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 154 TABLE 135 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 154 TABLE 136 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY REGION, 2022–2030 (USD MILLION) 155 TABLE 137 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 156 TABLE 138 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 156 TABLE 139 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 156 TABLE 140 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY REGION, 2022–2030 (USD MILLION) 158 TABLE 141 MACROECONOMIC INDICATORS FOR NORTH AMERICA 159 TABLE 142 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 161 TABLE 143 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 161 TABLE 144 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 162 TABLE 145 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 162 TABLE 146 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 163 TABLE 147 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 163 TABLE 148 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 164 TABLE 149 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 165 TABLE 150 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 166 TABLE 151 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 166 TABLE 152 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 167 TABLE 153 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 167 TABLE 154 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 168 TABLE 155 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 169 TABLE 156 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 170 TABLE 157 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 170 TABLE 158 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 171 TABLE 159 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 171 TABLE 160 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 172 TABLE 161 MACROECONOMIC INDICATORS FOR EUROPE 173 TABLE 162 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 174 TABLE 163 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 174 TABLE 164 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 175 TABLE 165 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 175 TABLE 166 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 176 TABLE 167 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 176 TABLE 168 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 177 TABLE 169 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 178 TABLE 170 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 179 TABLE 171 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 179 TABLE 172 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 180 TABLE 173 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 180 TABLE 174 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 181 TABLE 175 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 182 TABLE 176 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 182 TABLE 177 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 183 TABLE 178 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 183 TABLE 179 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 184 TABLE 180 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 184 TABLE 181 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 185 TABLE 182 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 186 TABLE 183 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 186 TABLE 184 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 187 TABLE 185 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 187 TABLE 186 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 188 TABLE 187 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 189 TABLE 188 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 190 TABLE 189 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 190 TABLE 190 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 191 TABLE 191 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 191 TABLE 192 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 192 TABLE 193 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 193 TABLE 194 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 193 TABLE 195 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 194 TABLE 196 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 194 TABLE 197 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 195 TABLE 198 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 195 TABLE 199 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 196 TABLE 200 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 197 TABLE 201 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 197 TABLE 202 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 198 TABLE 203 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 198 TABLE 204 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 199 TABLE 205 MACROECONOMIC INDICATORS FOR ASIA PACIFIC 199 TABLE 206 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 201 TABLE 207 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 201 TABLE 208 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 202 TABLE 209 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 202 TABLE 210 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 203 TABLE 211 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 203 TABLE 212 ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 204 TABLE 213 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 205 TABLE 214 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 206 TABLE 215 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 206 TABLE 216 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 207 TABLE 217 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 207 TABLE 218 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 208 TABLE 219 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 209 TABLE 220 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 210 TABLE 221 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 210 TABLE 222 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 211 TABLE 223 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 211 TABLE 224 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 212 TABLE 225 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 213 TABLE 226 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 214 TABLE 227 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 214 TABLE 228 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 215 TABLE 229 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 215 TABLE 230 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 216 TABLE 231 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 217 TABLE 232 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 217 TABLE 233 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 218 TABLE 234 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 218 TABLE 235 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 219 TABLE 236 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 219 TABLE 237 MACROECONOMIC INDICATORS FOR LATIN AMERICA 221 TABLE 238 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 221 TABLE 239 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 222 TABLE 240 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 222 TABLE 241 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 223 TABLE 242 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 223 TABLE 243 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 224 TABLE 244 MACROECONOMIC INDICATORS FOR MIDDLE EAST & AFRICA 225 TABLE 245 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 226 TABLE 246 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 226 TABLE 247 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 227 TABLE 248 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 227 TABLE 249 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 228 TABLE 250 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 228 TABLE 251 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, 2022–2025 229 TABLE 252 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DEGREE OF COMPETITION 233 TABLE 253 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: REGION FOOTPRINT 240 TABLE 254 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PRODUCT TYPE FOOTPRINT 241 TABLE 255 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: THERAPEUTIC AREA FOOTPRINT 242 TABLE 256 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PHASE FOOTPRINT 243 TABLE 257 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 246 TABLE 258 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 247 TABLE 259 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025 248 TABLE 260 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DEALS, JANUARY 2022–JANUARY 2025 249 TABLE 261 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: EXPANSIONS, JANUARY 2022–JANUARY 2025 250 TABLE 262 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2025 250 TABLE 263 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 251 TABLE 264 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 252 TABLE 265 THERMO FISHER SCIENTIFIC INC: PRODUCT LAUNCHES, JANUARY 2022– JANUARY 2025 253 TABLE 266 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JANUARY 2025 253 TABLE 267 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–JANUARY 2025 254 TABLE 268 IQVIA: COMPANY OVERVIEW 255 TABLE 269 IQVIA: PRODUCTS/SERVICES OFFERED 256 TABLE 270 IQVIA: PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025 257 TABLE 271 IQVIA: DEALS, JANUARY 2022–JANUARY 2025 258 TABLE 272 ICON PLC: COMPANY OVERVIEW 259 TABLE 273 ICON PLC: PRODUCTS/SERVICES OFFERED 260 TABLE 274 ICON PLC: PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025 260 TABLE 275 ICON PLC: DEALS, JANUARY 2022–JANUARY 2025 261 TABLE 276 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 262 TABLE 277 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED 263 TABLE 278 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–JANUARY 2025 264 TABLE 279 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–JANUARY 2025 265 TABLE 280 LABCORP: COMPANY OVERVIEW 266 TABLE 281 LABCORP: PRODUCTS/SERVICES OFFERED 267 TABLE 282 LABCORP: PRODUCTS LAUNCHES, JANUARY 2022–JANUARY 2025 268 TABLE 283 LABCORP: DEALS, JANUARY 2022–JANUARY 2025 268 TABLE 284 LABCORP: EXPANSIONS, JANUARY 2022–JANUARY 2025 269 TABLE 285 LABCORP: OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2025 269 TABLE 286 QUEST DIAGNOSTICS: COMPANY OVERVIEW 271 TABLE 287 QUEST DIAGNOSTICS: PRODUCTS/SERVICES OFFERED 272 TABLE 288 QUEST DIAGNOSTICS: DEALS, JANUARY 2022–JANUARY 2025 272 TABLE 289 MEDPACE: COMPANY OVERVIEW 274 TABLE 290 MEDPACE: PRODUCTS/SERVICES OFFERED 275 TABLE 291 MEDPACE: EXPANSIONS, JANUARY 2022–JANUARY 2025 275 TABLE 292 FRONTAGE LABS: COMPANY OVERVIEW 276 TABLE 293 FRONTAGE LABS: PRODUCTS/SERVICES OFFERED 277 TABLE 294 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY OVERVIEW 279 TABLE 295 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: PRODUCTS/SERVICES OFFERED 280 TABLE 296 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: DEALS, JANUARY 2022– JANUARY 2025 281 TABLE 297 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 282 TABLE 298 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED 283 TABLE 299 EUROFINS SCIENTIFIC: DEALS, JANUARY 2022–JANUARY 2025 284 TABLE 300 REPROCELL INC.: COMPANY OVERVIEW 285 TABLE 301 REPROCELL INC.: PRODUCTS/SERVICES OFFERED 285 TABLE 302 REPROCELL INC.: DEALS, JANUARY 2022–JANUARY 2025 286 TABLE 303 ACM GLOBAL LABORATORIES: COMPANY OVERVIEW 287 TABLE 304 ACM GLOBAL LABORATORIES: PRODUCTS/SERVICES OFFERED 287 TABLE 305 ACM GLOBAL LABORATORIES: DEALS, JANUARY 2022–JANUARY 2025 288 TABLE 306 WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW 289 TABLE 307 VERSITI: COMPANY OVERVIEW 290 TABLE 308 CTI CLINICAL TRIAL & CONSULTING: COMPANY OVERVIEW 291 TABLE 309 CLARITY LABORATORIES, INC: COMPANY OVERVIEW 292 TABLE 310 NOVOTECH: COMPANY OVERVIEW 293 TABLE 311 ARUP LABORATORIES: COMPANY OVERVIEW 294 TABLE 312 PRECISION MEDICINE GROUP: COMPANY OVERVIEW 295 TABLE 313 BIOAGILYTIX LABS: COMPANY OVERVIEW 296 TABLE 314 CERBA HEALTHCARE: COMPANY OVERVIEW 297 TABLE 315 ALMAC GROUP: COMPANY OVERVIEW 298 TABLE 316 MLM MEDICAL LABS: COMPANY OVERVIEW 299 TABLE 317 SALVUS BIORESEARCH SOLUTIONS LLP: COMPANY OVERVIEW 300 TABLE 318 UNILABS: COMPANY OVERVIEW 301 FIGURE 1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SEGMENTATION AND REGIONAL SCOPE 32 FIGURE 2 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: RESEARCH DESIGN 35 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 40 FIGURE 4 COMPANY REVENUE ESTIMATION APPROACH: BOTTOM-UP APPROACH 41 FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42 FIGURE 6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: TOP-DOWN APPROACH 42 FIGURE 7 DATA TRIANGULATION METHODOLOGY 44 FIGURE 8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2025 VS. 2030 (USD MILLION) 47 FIGURE 9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2025 VS. 2030 (USD MILLION) 48 FIGURE 10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 49 FIGURE 11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION) 49 FIGURE 12 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 50 FIGURE 13 GEOGRAPHICAL SNAPSHOT OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET 51 FIGURE 14 INCREASING PREVALENCE OF RARE DISEASES TO DRIVE MARKET 52 FIGURE 15 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT AND CHINA LED ASIA PACIFIC MARKET IN 2024 53 FIGURE 16 CHINA TO RECORD HIGHEST GROWTH RATE FROM 2025 TO 2030 54 FIGURE 17 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 55 FIGURE 18 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56 FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 64 FIGURE 20 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: VALUE CHAIN ANALYSIS 66 FIGURE 21 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: ECOSYSTEM ANALYSIS 67 FIGURE 22 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: INVESTMENT AND FUNDING SCENARIO, 2022−2025 68 FIGURE 23 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 81 FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 83 FIGURE 25 KEY BUYING CRITERIA, BY END USER 84 FIGURE 26 AI USE CASES 86 FIGURE 27 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SNAPSHOT 160 FIGURE 28 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SNAPSHOT 200 FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS, 2020−2024 (USD MILLION) 232 FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 233 FIGURE 31 RANKING OF KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, 2024 234 FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025 235 FIGURE 33 FINANCIAL METRICS, 2025 235 FIGURE 34 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: BRAND/PRODUCT COMPARISON 236 FIGURE 35 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 238 FIGURE 36 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPANY FOOTPRINT 239 FIGURE 37 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 245 FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 252 FIGURE 39 IQVIA: COMPANY SNAPSHOT (2024) 256 FIGURE 40 ICON PLC: COMPANY SNAPSHOT (2023) 259 FIGURE 41 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023) 263 FIGURE 42 LABCORP: COMPANY SNAPSHOT (2024) 267 FIGURE 43 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2024) 271 FIGURE 44 MEDPACE: COMPANY SNAPSHOT (2024) 274 FIGURE 45 FRONTAGE LABS: COMPANY SNAPSHOT (2023) 277 FIGURE 46 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2024) 280 FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 283

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們